Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy

Investigational New Drugs

Volumn 32, Issue 1, 2014, Pages 47-59

  Chow, Annabelle ^a   Wong, Amy ^a   Francia, Giulio ^b   Man, Shan ^a   Kerbel, Robert S ^a   Emmenegger, Urban ^a,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TEXAS AT EL PASO   (United States)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Cyclophosphamide; Docetaxel; Drug resistance; Low dose metronomic chemotherapy; Maximum tolerated dose chemotherapy; Prostate cancer

Indexed keywords

ADMINISTRATION, METRONOMIC; ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FECAL IMPACTION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE ONTOLOGY; HUMANS; MALE; MICE; MICE, NUDE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATIC NEOPLASMS; TAXOIDS; TOPOTECAN; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899111490     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-9974-3     Document Type: Article

References (62)

1. Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4(6):423-436 (Pubitemid 38745528)
2. Pasquier E, Kavallaris M, Andre N (2010) Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 7(8):455-465. doi:10.1038/nrclinonc.2010.82
3. Nelius T, Rinard K, Filleur S (2011) Oral/metronomic cyclophosphamide- based chemotherapy as option for patients with castration-refractory prostate cancer: review of the literature. Cancer Treat Rev 37(6):444-455. doi:10.1016/j.ctrv.2010.12.006
4. Emmenegger U, Francia G, Shaked Y, Kerbel RS (2010) Metronomic chemotherapy: principles and lessons learned from applications in the treatment of metastatic prostate cancer. Recent Results Cancer Res 180:165-183. doi:10.1007/978-3-540-78281-0-10
5. Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, Watanabe Y, Wada H, Tsuboi M, Hamajima N (2004) A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350(17):1713-1721 (Pubitemid 38501140)
6. Watanabe T, Sano M, Takashima S, Kitaya T, Tokuda Y, Yoshimoto M, Kohno N, Nakagami K, Iwata H, Shimozuma K, Sonoo H, Tsuda H, Sakamoto G, Ohashi Y (2009) Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial. J Clin Oncol 27(9):1368-1374
7. Bottini A, Generali D, Brizzi MP, Fox SB, Bersiga A, Bonardi S, Allevi G, Aguggini S, Bodini G, Milani M, Dionisio R, Bernardi C, Montruccoli A, Bruzzi P, Harris AL, Dogliotti L, Berruti A (2006) Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol 24(22):3623-3628 (Pubitemid 46630536)
8. Borne E, Desmedt E, Duhamel A, Mirabel X, Dziwniel V, Maire C, Florin V, Martinot V, Penel N, Vercambre-Darras S, Mortier L (2009) Oral metronomic cyclophosphamide in elderly with metastatic melanoma. Invest New Drugs. doi:10.1007/s10637-009-9298-5
9. Fontana A, Falcone A, Derosa L, Di Desidero T, Danesi R, Bocci G (2010) Metronomic chemotherapy for metastatic prostate cancer: a 'young' concept for old patients? Drugs Aging 27(9):689-696. doi:10.2165/11537480-000000000-00000
10. Fontana A, Bocci G, Galli L, D'Arcangelo M, Derosa L, Fioravanti A, Orlandi P, Barletta MT, Landi L, Bursi S, Minuti G, Bona E, Grazzini I, Danesi R, Falcone A (2010) Metronomic cyclophosphamide in elderly patients with advanced, castration-resistant prostate cancer. J Am Geriatr Soc 58(5):986-988. doi:10.1111/j.1532-5415.2010.02833.x
11. Kerbel RS (2012) Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer. Journal of Mammary Gland Biology and Neoplasia 17(3-4):229-239. doi:10.1007/s10911-012-9266-0
12. Folkins C, Man S, Xu P, Shaked Y, Hicklin DJ, Kerbel RS (2007) Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res 67(8):3560-3564 (Pubitemid 46762138)
13. Martin-Padura I, Marighetti P, Agliano A, Colombo F, Larzabal L, Redrado M, Bleau AM, Prior C, Bertolini F, Calvo A (2012) Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts. Lab Invest 92(7):952-966. doi:10.1038/labinvest.2012.65
14. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60(7):1878-1886 (Pubitemid 30207647)
15. Emmenegger U, Francia G, Chow A, Shaked Y, Kouri A, Man S, Kerbel RS (2011) Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide. Neoplasia 13(1):40-48
16. Thoenes L, Hoehn M, Kashirin R, Ogris M, Arnold GJ, Wagner E, Guenther M (2010) In vivo chemoresistance of prostate cancer in metronomic cyclophosphamide therapy. J Proteomics 73(7):1342-1354. doi:10.1016/j.jprot.2010.02.019
17. Emmenegger U, Morton GC, Francia G, Shaked Y, Franco M, Weinerman A, Man S, Kerbel RS (2006) Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia. Cancer Res 66(3):1664-1674 (Pubitemid 43259951)
18. Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, Bohlen P, Hicklin DJ, Bergers G, Kerbel RS (2002) Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 62(10):2731-2735 (Pubitemid 34525751)
19. Shaked Y, Emmenegger U, Francia G, Chen L, Lee CR, Man S, Paraghamian A, Ben-David Y, Kerbel RS (2005) Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res 65(16):7045-7051 (Pubitemid 41161230)
20. Graham MA, Senan S, Robin H Jr, Eckhardt N, Lendrem D, Hincks J, Greenslade D, Rampling R, Kaye SB, von Roemeling R, Workman P (1997) Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial. Cancer Chemother Pharmacol 40(1):1-10 (Pubitemid 27160953)
21. Hashimoto K, Man S, Xu P, Cruz-Munoz W, Tang T, Kumar R, Kerbel RS (2010) Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol Cancer Ther 9(4):996-1006. doi:10.1158/1535-7163.MCT-09-0960
22. Gerber HP, Ferrara N (2005) Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65(3):671-680
23. Shaked Y, Emmenegger U, Man S, Cervi D, Bertolini F, Ben-David Y, Kerbel RS (2005) Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 106(9):3058-3061. doi:10.1182/blood-2005-04-1422 (Pubitemid 41565900)
24. Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98(9):5116-5121. doi:10.1073/pnas.091062498 (Pubitemid 32397092)
25. da Huang W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4(1):44-57. doi:10.1038/nprot.2008.211
26. da Huang W, Sherman BT, Lempicki RA (2009) Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37(1):1-13. doi:10.1093/nar/gkn923
27. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502-1512 (Pubitemid 39315317)
28. Sanborn SL, Cooney MM, Dowlati A, Brell JM, Krishnamurthi S, Gibbons J, Bokar JA, Nock C, Ness A, Remick SC (2008) Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles. Invest New Drugs 26(4):355-362. doi:10.1007/s10637-008-9137-0
29. Gorn M, Habermann CR, Anige M, Thom I, Schuch G, Andritzky B, Brandl S, Burkholder I, Edler L, Hossfeld DK, Bokemeyer C, Laack E (2008) A pilot study of docetaxel and trofosfamide as second-line 'metronomic' chemotherapy in the treatment of metastatic non-small cell lung cancer (NSCLC). Onkologie 31(4):185-189. doi:10.1159/000118626 (Pubitemid 351700542)
30. Young SD, Lafrenie RM, Clemons MJ (2012) Phase ii trial of a metronomic schedule of docetaxel and capecitabine with concurrent celecoxib in patients with prior anthracycline exposure for metastatic breast cancer. Curr Oncol 19(2):e75-e83. doi:10.3747/co.19.879
31. Facchini G, Caraglia M, Morabito A, Marra M, Piccirillo MC, Bochicchio AM, Striano S, Marra L, Nasti G, Ferrari E, Leopardo D, Vitale G, Gentilini D, Tortoriello A, Catalano A, Budillon A, Perrone F, Iaffaioli RV (2010) Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients: phase I ZANTE trial. Cancer Biol Ther 10(6):543-548. doi:10.4161/cbt.10.6.12611
32. Ng SS, Sparreboom A, Shaked Y, Lee C, Man S, Desai N, Soon-Shiong P, Figg WD, Kerbel RS (2006) Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel. Clin Cancer Res 12(14 Pt 1):4331-4338
33. Wu H, Xin Y, Xiao Y, Zhao J (2012) Low-dose docetaxel combined with (-)-epigallocatechin-3-gallate inhibits angiogenesis and tumor growth in nude mice with gastric cancer xenografts. Cancer Biother Radiopharm 27(3):204-209. doi:10.1089/cbr.2011.1103
34. Wu H, Xin Y, Zhao J, Sun D, Li W, Hu Y, Wang S (2011) Metronomic docetaxel chemotherapy inhibits angiogenesis and tumor growth in a gastric cancer model. Cancer Chemother Pharmacol 68(4):879-887. doi:10.1007/s00280-011- 1563-6
35. Kamat AA, Kim TJ, Landen CN Jr, Lu C, Han LY, Lin YG, Merritt WM, Thaker PH, Gershenson DM, Bischoff FZ, Heymach JV, Jaffe RB, Coleman RL, Sood AK (2007) Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res 67(1):281-288 (Pubitemid 46142786)
36. Newman SP, Foster PA, Ho YT, Day JM, Raobaikady B, Kasprzyk PG, Leese MP, Potter BV, Reed MJ, Purohit A (2007) The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancers. Br J Cancer 97(12):1673-1682. doi:10.1038/sj.bjc.6604100 (Pubitemid 350249364)
37. Muramaki M, Miyake H, Hara I, Kamidono S (2005) Synergistic inhibition of tumor growth and metastasis by combined treatment with TNP-470 and docetaxel in a human prostate cancer PC-3 model. Int J Oncol 26(3):623-628
38. Hackl C, Man S, Francia G, Milsom C, Xu P, Kerbel RS (2012) Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models. Gut. doi:10.1136/gutjnl-2011-301585
39. Merritt WM, Danes CG, Shahzad MM, Lin YG, Kamat AA, Han LY, Spannuth WA, Nick AM, Mangala LS, Stone RL, Kim HS, Gershenson DM, Jaffe RB, Coleman RL, Chandra J, Sood AK (2009) Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. Cancer Biol Ther 8(16):1596-1603
40. Kumar S, Mokhtari RB, Sheikh R, Wu B, Zhang L, Xu P, Man S, Oliveira ID, Yeger H, Kerbel RS, Baruchel S (2011) Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor. Clin Cancer Res 17(17):5656-5667. doi:10.1158/1078-0432.CCR-11-0078
41. du Manoir JM, Francia G, Man S, Mossoba M, Medin JA, Viloria-Petit A, Hicklin DJ, Emmenegger U, Kerbel RS (2006) Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clin Cancer Res 12(3 Pt 1):904-916 (Pubitemid 43259873)
42. Tam L, McGlynn LM, Traynor P, Mukherjee R, Bartlett JM, Edwards J (2007) Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer. Br J Cancer 97(3):378-383. doi:10.1038/sj.bjc.6603871 (Pubitemid 47196744)
43. Chang YM, Kung HJ, Evans CP (2007) Nonreceptor tyrosine kinases in prostate cancer. Neoplasia 9(2):90-100
44. Paulo P, Barros-Silva JD, Ribeiro FR, Ramalho-Carvalho J, Jeronimo C, Henrique R, Lind GE, Skotheim RI, Lothe RA, Teixeira MR (2012) FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer. Genes Chromosomes Cancer 51(3):240-249. doi:10.1002/gcc.20948
45. Erkizan HV, Uversky VN, Toretsky JA (2010) Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma. Clin Cancer Res 16(16):4077-4083. doi:10.1158/1078-0432.CCR-09-2261
46. di Masi A, Gullotta F, Cappadonna V, Leboffe L, Ascenzi P (2011) Cancer predisposing mutations in BRCT domains. IUBMB life 63(7):503-512. doi:10.1002/iub.472
47. Bocci G, Francia G, Man S, Lawler J, Kerbel RS (2003) Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci U S A 100(22):12917-12922 (Pubitemid 37340000)
48. Jia L, Waxman DJ (2013) Thrombospondin-1 and pigment epithelium-derived factor enhance responsiveness of KM12 colon tumor to metronomic cyclophosphamide but have disparate effects on tumor metastasis. Cancer Lett 330(2):241-249. doi:10.1016/j.canlet.2012.11.055
49. Chabner BA, Roberts TG Jr (2005) Timeline: chemotherapy and the war on cancer. Nat Rev Cancer 5(1):65-72. doi:10.1038/nrc1529
50. Raguz S, Yague E (2008) Resistance to chemotherapy: new treatments and novel insights into an old problem. Br J Cancer 99(3):387-391. doi:10.1038/sj.bjc.6604510
51. Bock C, Lengauer T (2012) Managing drug resistance in cancer: lessons from HIV therapy. Nat Rev Cancer 12(7):494-501. doi:10.1038/nrc3297
52. Aljuffali IA, Mock JN, Costyn LJ, Nguyen H, Nagy T, Cummings BS, Arnold RD (2011) Enhanced antitumor activity of low-dose continuous administration schedules of topotecan in prostate cancer. Cancer Biol Ther 12(5):407-420
53. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15(3):232-239. doi:10.1016/j.ccr.2009.01.021
54. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15(3):220-231
55. De Souza R, Zahedi P, Badame RM, Allen C, Piquette-Miller M (2011) Chemotherapy dosing schedule influences drug resistance development in ovarian cancer. Mol Cancer Ther 10(7):1289-1299. doi:10.1158/1535-7163.MCT-11-0058
56. De Souza R, Zahedi P, Moriyama EH, Allen CJ, Wilson BC, Piquette-Miller M (2010) Continuous docetaxel chemotherapy improves therapeutic efficacy in murine models of ovarian cancer. Mol Cancer Ther 9(6):1820-1830. doi:10.1158/1535-7163.MCT-10-0249
57. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS (2000) Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105(8):R15-R24 (Pubitemid 30217701)
58. Ma L, Francia G, Viloria-Petit A, Hicklin DJ, du Manoir J, Rak J, Kerbel RS (2005) In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy. Cancer Res 65(12):5365-5373 (Pubitemid 40827350)
59. Ranpura V, Hapani S, Wu S (2011) Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. Jama 305(5):487-494. doi:10.1001/jama.2011.51
60. Ebos JM, Lee CR, Kerbel RS (2009) Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res 15(16):5020-5025. doi:10.1158/1078-0432.CCR-09-0095
61. Verstovsek S (2013) Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis. Postgraduate medicine 125(1):128-135. doi:10.3810/pgm.2013.01.2628
62. Kubisch R, Meissner L, Krebs S, Blum H, Gunther M, Roidl A, Wagner E (2013) A comprehensive gene expression analysis of resistance formation upon metronomic cyclophosphamide therapy. Transl Oncol 6(1):1-9